While Obstructive Sleep Apnea (OSA) affects about five percent of the general pediatric population, 80 percent of children with Down syndrome experience OSA. Continual OSA results in poor health, including disruptions to cognitive development and functioning, leading physician-researchers from Mass General Brigham to investigate better methods to treat these patients as early as possible to maximize their health outcomes.
Strides Pharma gets FDA greenlight to market HIV treatment – Pharmaceutical Technology
The three tablets, Efavirenz, Emtricitabine and Tenofovir Disproxil Fumurate, known collectively as EET, have all seen approval as generic alternatives to Gilead’s Atripla. Credit: Shutterstock
October 4, 2023